Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 10, 2010, Pages 1467-1473

  Łukaszewicz Zaja̧c, Marta ^a   Mroczko, Barbara ^a   Kozłowski, Mirosław ^a   Nikliński, Jacek ^a   Laudański, Jerzy ^a   Szmitkowski, MacIej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

esophageal cancer; M CSF; tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; SQUAMOUS CELL CANCER ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC VALUE; DISTANT METASTASIS; ENZYME IMMUNOASSAY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958177268     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.274     Document Type: Article

References (30)

1. McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, et al. Circulating macrophage colony stimulating factor as a marker of tumor progression. Eur Cytokine Netw 2002;13:121-7.
2. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Sympt Manage 2000;20:214-32.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
4. Oka M, Hirose K, Iizuka N, Aoyagi K, Yamamoto K, Abe T, et al. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995;15:1005-9.
5. Mroczko B, Szmitkowski M, Okulczyk B. Hematopoietic growth factor in colorectal cancer patients. Clin Chem Lab Med 2003;41:646-51.
6. Kamińska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumour Biol 2005;26:186-94.
7. Mroczko B, Wereszczyńska-Siemia̧tkowska U, Groblewska M, Łukaszewicz M, Szmitkowski M, Gryko M, et al. The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. Clin Chim Acta 2006;374:165-7.
8. Mroczko B, Szmitkowski M. Macrophage-colony stimulating factor (M-CSF) in diagnostic and monitoring of non-small-cell lung cancer (NSCLC). Pol Arch Med Wewn 2001;105:203-9.
9. Mroczko B, Szmitkowski M, Wereszczyńska-Siemia̧tkowska U, Jurkowska G. Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clin Chem Lab Med 2005;43:146-50.
10. Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Myśliwiec P, Kedra B, Szmitkowski M. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med 2007;45:30-4.
11. Samantaray S, Sharma R, Chattopadhyaya TK, Datta Gupta S, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004;130:37-44.
12. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856-62.
13. Jass JR, Sobin LH. WHO international histological classification of tumors. Histological typing of intestinal tumors. New York: Springer-Verlag, 1989.
14. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996;56:2776-80.
15. Mroczko B, Szmitkowski M, Nikliński J. Granulocyte colonystimulating factor and macrophage colony-stimulating factor in patients with non-small-cell lung cancer. Clin Chem Lab Med 2001;39:374-9.
16. Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 2009;33:272-7.
17. Kimura H, Kato H, Tanaka N, Inose T, Faried A, Sohda M, et al. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008;28:165-9.
18. Yildirim A, Bilici M, Cayir K, Yanmaz V, Yildirim S, Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009;39:92-6.
19. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000;6:4249-52.
20. Asakura E, Hanamura T, Umemura A, Yada K, Yamauchi T, Tanabe T. Effects of macrophage colony-stimulating factor (M-CSF) on lipopolysaccharide (LPS)-induced mediator production from monocytes in vitro. Immunobiology 1996;195:300-13.
21. Hamilton JA, Whitty GA, Stanton H, Meager A. Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-alpha. J Leukoc Biol 1993;53:707-14.
22. Lahm H, Wyniger J, Hertig S, Yilmaz A, Fischer JR, Givel JC, et al. Secretion of bioactive granulocyte-macrophage colonystimulating factor by human colorectal carcinoma cells. Cancer Res 1994;54:3700-2.
23. Calatayud S, Warner TD, Breese EJ, Mitchell JA. Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. Cytokine 2002;20:163-7.
24. Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, et al. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest 2002;82:1481-92.
25. Mroczko B, Szmitkowski M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B. Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer. Int J Colorectal Dis 2007;22:33-8.
26. Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B, Łaszewicz W, et al. Serum macrophagecolony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007;380:208-12.
27. Mroczko B, Szmitkowski M, Wereszczynska-Siemiatkowska U, Jurkowska G. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer. Clin Chem Lab Med 2004;42:256-60.
28. Ławicki S, Szmitkowski M, Wojtukiewicz M. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta 2006;371:112-6.
29. Shimada Y, Maeda M, Watanabe G, Imamura M. High serum soluble E-selectin levels are associated with postoperative haematogenic recurrence in esophageal squamous cell carcinoma patients. Oncol Rep 2003;10:991-5.
30. Tezuka Y, Yonezawa S, Maruyama I, Matsushita Y, Shimizu T, Obama H, et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res 1995;55:4196-200.